

Silvia Biocca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/401260/publications.pdf>

Version: 2024-02-01

76
papers

2,853
citations

182225

30
h-index

198040

52
g-index

78
all docs

78
docs citations

78
times ranked

3034
citing authors

#	ARTICLE	IF	CITATIONS
1	Intestinal Taxa Abundance and Diversity in Inflammatory Bowel Disease Patients: An Analysis including Covariates and Confounders. <i>Nutrients</i> , 2022, 14, 260.	1.7	21
2	Combined and selective miR-21 silencing and doxorubicin delivery in cancer cells using tailored DNA nanostructures. <i>Cell Death and Disease</i> , 2021, 12, 7.	2.7	22
3	Gut microbiota dysbiosis in Parkinson's disease patients: Early feature and biomarker of disease progression?. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119515.	0.3	0
4	AS1411 Aptamer Linked to DNA Nanostructures Diverts Its Traffic Inside Cancer Cells and Improves Its Therapeutic Efficacy. <i>Pharmaceutics</i> , 2021, 13, 1671.	2.0	21
5	In Silico and In Cell Analysis of Openable DNA Nanocages for miRNA Silencing. <i>International Journal of Molecular Sciences</i> , 2020, 21, 61.	1.8	9
6	A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab. <i>Clinical and Experimental Dermatology</i> , 2020, 45, 809-810.	0.6	0
7	Can Gut Microbiota Be a Good Predictor for Parkinson's Disease? A Machine Learning Approach. <i>Brain Sciences</i> , 2020, 10, 242.	1.1	22
8	Dysbiosis of gut microbiota in a selected population of Parkinson's patients. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 124-130.	1.1	144
9	Cellular uptake of covalent and non-covalent DNA nanostructures with different sizes and geometries. <i>Nanoscale</i> , 2019, 11, 10808-10818.	2.8	42
10	Effect of Low-Protein Diet and Inulin on Microbiota and Clinical Parameters in Patients with Chronic Kidney Disease. <i>Nutrients</i> , 2019, 11, 3006.	1.7	40
11	Selective targeting and degradation of doxorubicin-loaded folate-functionalized DNA nanocages. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 1181-1190.	1.7	59
12	Membrane cholesterol depletion in cortical neurons highlights altered NMDA receptor functionality in a mouse model of amyotrophic lateral sclerosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 509-519.	1.8	13
13	Entry, fate and degradation of DNA nanocages in mammalian cells: a matter of receptors. <i>Nanoscale</i> , 2018, 10, 12078-12086.	2.8	30
14	Cholesterol level regulates lectin-like oxidized low-density lipoprotein receptor-1 function. <i>Biomedical Spectroscopy and Imaging</i> , 2016, 5, S87-S99.	1.2	5
15	The lectin-like oxidized LDL receptor-1: a new potential molecular target in colorectal cancer. <i>Oncotarget</i> , 2016, 7, 14765-14780.	0.8	45
16	Receptor-Mediated Entry of Pristine Octahedral DNA Nanocages in Mammalian Cells. <i>ACS Nano</i> , 2016, 10, 5971-5979.	7.3	76
17	DNA hairpins promote temperature controlled cargo encapsulation in a truncated octahedral nanocage structure family. <i>Nanoscale</i> , 2016, 8, 13333-13341.	2.8	28
18	Molecular mechanism of statin-mediated LOX-1 inhibition. <i>Cell Cycle</i> , 2015, 14, 1583-1595.	1.3	36

#	ARTICLE	IF	CITATIONS
19	The Potential of Nucleic Acid-Based Nanoparticles for Biomedical Application. Nano LIFE, 2015, 05, 1541004.	0.6	5
20	Intrabody-mediated diverting of HP1 ² to the cytoplasm induces co-aggregation of H3 ² H4 histones and lamin-B receptor. Experimental Cell Research, 2015, 338, 70-81.	1.2	6
21	Membrane Cholesterol Modulates LOX-1 Shedding in Endothelial Cells. PLoS ONE, 2015, 10, e0141270.	1.1	22
22	Therapeutic Application of Intrabodies Against Age-Related Neurodegenerative Disorders. Current Pharmaceutical Design, 2014, 20, 6028-6036.	0.9	8
23	Design of a novel LOX-1 receptor antagonist mimicking the natural substrate. Biochemical and Biophysical Research Communications, 2013, 438, 340-345.	1.0	29
24	Simulative and experimental investigation on the cleavage site that generates the soluble human LOX-1. Archives of Biochemistry and Biophysics, 2013, 540, 9-18.	1.4	17
25	Gene-Based Antibody Strategies for Prion Diseases. International Journal of Cell Biology, 2013, 2013, 1-6.	1.0	11
26	Cholesterol-Lowering Drugs Inhibit Lectin-Like Oxidized Low-Density Lipoprotein-1 Receptor Function by Membrane Raft Disruption. Molecular Pharmacology, 2012, 82, 246-254.	1.0	65
27	Altered Intracellular Distribution of PrPC and Impairment of Proteasome Activity in Tau Overexpressing Cortical Neurons. Journal of Alzheimer's Disease, 2011, 27, 603-613.	1.2	10
28	Intrabody Expression in Mammalian Cells. Cell Engineering, 2011, , 179-195.	0.4	1
29	LOX-1 as a natural IFN- γ -mediated signal for apoptotic cell uptake and antigen presentation in dendritic cells. Blood, 2010, 115, 1554-1563.	0.6	70
30	Expressing Intrabodies in Mammalian Cells. , 2010, , 161-172.		2
31	Functional Analysis and Molecular Dynamics Simulation of LOX-1 K167N Polymorphism Reveal Alteration of Receptor Activity. PLoS ONE, 2009, 4, e4648.	1.1	53
32	Can intrabodies targeted to the secretory compartment interact with a cytosolic protein? A comment on the article by Sawahata et al. "Cytoplasmic expression and specific binding of the VH/VL single domain intrabodies in transfected NIH3T3 cells", Exp. Mol. Pathol. 2008 Nov 27; Epub ahead of print. Experimental and Molecular Pathology, 2009, 86, 138.	0.9	1
33	The potential of intracellular antibodies for therapeutic targeting of protein-misfolding diseases. Trends in Molecular Medicine, 2008, 14, 373-380.	3.5	53
34	The splice variant LOXIN inhibits LOX-1 receptor function through hetero-oligomerization. Journal of Molecular and Cellular Cardiology, 2008, 44, 561-570.	0.9	66
35	Combating Protein Misfolding and Aggregation by Intracellular Antibodies. Current Molecular Medicine, 2008, 8, 2-11.	0.6	12
36	Molecular dynamics simulation of human LOX-1 provides an explanation for the lack of OxLDL binding to the Trp150Ala mutant. BMC Structural Biology, 2007, 7, 73.	2.3	25

#	ARTICLE	IF	CITATIONS
37	Selective re-routing of prion protein to proteasomes and alteration of its vesicular secretion prevent PrPSc formation. <i>Journal of Neurochemistry</i> , 2007, 101, 1516-1526.	2.1	28
38	Alterations of nuclear envelope and chromatin organization in mandibuloacral dysplasia, a rare form of laminopathy. <i>Physiological Genomics</i> , 2005, 23, 150-158.	1.0	112
39	In Vivo and In Vitro Studies Support That a New Splicing Isoform of OLR1 Gene Is Protective Against Acute Myocardial Infarction. <i>Circulation Research</i> , 2005, 97, 152-158.	2.0	116
40	KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity. <i>Biochemical and Biophysical Research Communications</i> , 2005, 338, 1791-1797.	1.0	44
41	Trapping Prion Protein in the Endoplasmic Reticulum Impairs PrPC Maturation and Prevents PrPSc Accumulation. <i>Journal of Biological Chemistry</i> , 2005, 280, 685-694.	1.6	72
42	Intracellular targeting and functional analysis of single-chain Fv fragments in mammalian cells. <i>Methods</i> , 2004, 34, 171-178.	1.9	32
43	Evidence for proteasome dysfunction in cytotoxicity mediated by anti-Ras intracellular antibodies. <i>FEBS Journal</i> , 2003, 270, 3389-3397.	0.2	15
44	Re: Blocking Oncogenic Ras Signaling for Cancer Therapy. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1031-1032.	3.0	11
45	Loss of Heterochromatin Protein 1 (HP1) chromodomain function in mammalian cells by intracellular antibodies causes cell death. <i>Journal of Cell Science</i> , 2002, 115, 1803-1813.	1.2	28
46	Loss of heterochromatin protein 1 (HP1) chromodomain function in mammalian cells by intracellular antibodies causes cell death. <i>Journal of Cell Science</i> , 2002, 115, 1803-13.	1.2	18
47	Aggresome formation by anti-Ras intracellular scFv fragments. <i>FEBS Journal</i> , 2001, 268, 268-277.	0.2	39
48	Expressing Intracellular Single-Chain Fv Fragments in Mammalian Cells. , 2001, , 755-774.		0
49	Diverting a protein from its cellular location by intracellular antibodies. <i>FEBS Journal</i> , 2000, 267, 1196-1205.	0.2	62
50	The selection of intracellular antibodies. <i>Trends in Biotechnology</i> , 1999, 17, 115-121.	4.9	140
51	The mode of action of Y13-259 scFv fragment intracellularly expressed in mammalian cells. <i>FEBS Letters</i> , 1998, 439, 197-202.	1.3	36
52	Assembled IgG Molecules Are Exported from the Endoplasmic Reticulum in Myeloma Cells Despite the Retention Signal Sekdel. <i>Biochemical and Biophysical Research Communications</i> , 1998, 246, 518-523.	1.0	0
53	Current Methods for Genotypic and Phenotypic Knock-Outs in Mammalian Cells. , 1997, , 9-14.		0
54	Intracellular Immunization. , 1997, , 105-124.		0

#	ARTICLE	IF	CITATIONS
55	Protein Sequence Motifs Involved in Intracellular Trafficking. , 1997, , 59-83.		0
56	From Phage Libraries to Intracellular Immunization. , 1997, , 173-186.		1
57	Perspectives and Conclusions. , 1997, , 187-189.		0
58	Assembly and Folding of Antibodies in Natural and Artificial Environments. , 1997, , 41-57.		0
59	Intracellular and Intercellular Immunization. , 1997, , 1-7.		1
60	Human recombinant antibody fragments neutralizing human immunodeficiency virus type 1 reverse transcriptase provide an experimental basis for the structural classification of the DNA polymerase family. Journal of Virology, 1996, 70, 7706-7712.	1.5	23
61	Intracellular immunization: antibody targeting to subcellular compartments. Trends in Cell Biology, 1995, 5, 248-252.	3.6	108
62	Redox State of Single Chain Fv Fragments Targeted to the Endoplasmic Reticulum, Cytosol and Mitochondria. Bio/technology, 1995, 13, 1110-1115.	1.9	170
63	The S-100: A protein family in search of a function. Progress in Neurobiology, 1995, 46, 71-82.	2.8	205
64	Intracellular Immunization with Cytosolic Recombinant Antibodies. Bio/technology, 1994, 12, 396-399.	1.9	94
65	Intracellular Expression of Anti-p21ras Single Chain Fv Fragments Inhibits Meiotic Maturation of Xenopus Oocytes. Biochemical and Biophysical Research Communications, 1993, 197, 422-427.	1.0	74
66	?Phytoantibodies?: a general vector for the expression of immunoglobulin domains in transgenic plants. Plant Molecular Biology, 1991, 17, 865-874.	2.0	91
67	Neuroantibodies: molecular cloning of a monoclonal antibody against substance P for expression in the central nervous system.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 5611-5615.	3.3	31
68	Intracellular immunization. FEBS Letters, 1990, 274, 193-198.	1.3	46
69	Synthesis and content of a DNA-binding protein with lactic dehydrogenase activity are reduced by nerve growth factor in the neoplastic cell line PC12. Experimental Cell Research, 1985, 161, 117-129.	1.2	28
70	Nuclear localization of a lactic dehydrogenase with single-stranded DNA-binding properties. Experimental Cell Research, 1985, 161, 130-140.	1.2	48
71	The nerve growth factor *1Established findings and controversial aspects. Experimental Cell Research, 1984, 154, 1-9.	1.2	47
72	Nerve growth factor inhibits the synthesis of a single-stranded DNA binding protein in pheochromocytoma cells (clone PC12).. Proceedings of the National Academy of Sciences of the United States of America, 1984, 81, 2080-2084.	3.3	10

#	ARTICLE	IF	CITATIONS
73	Hidden receptors for nerve growth factor in PC12 cells. FEBS Journal, 1983, 135, 285-290.	0.2	21
74	Morphological and ultrastructural changes in PC12 pheochromocytoma cells induced by a combined treatment with NGF and taxol. Experimental Cell Research, 1982, 142, 385-395.	1.2	14
75	Cell Density Modulates Receptor-Mediated Internalization of Nerve Growth Factor in Pheochromocytoma Cells. Journal of Receptors and Signal Transduction, 1980, 1, 373-387.	1.2	6
76	Preparation of highly 3H-labeled S-100 protein under nondenaturing conditions. Analytical Biochemistry, 1978, 87, 334-342.	1.1	13